Post-transplant Lymphoproliferative Disorders After Liver Transplantation: A Retrospective Cohort Study Including 1954 Transplants.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
29
01
2021
received:
21
11
2020
accepted:
17
02
2021
pubmed:
4
3
2021
medline:
12
8
2021
entrez:
3
3
2021
Statut:
ppublish
Résumé
Post-transplant lymphoproliferative disorders (PTLDs) are life-threatening neoplasms after organ transplantation. Because of their rarity and multiple grades of malignancy, the incidence, outcomes, and clinicopathological features affecting patient survival after liver transplantation (LT) remain unclear. We reviewed 1954 LTs in 1849 recipients (1990-2020), including 886 pediatric (<18 years of age) and 963 adult recipients. The following clinicopathological factors were studied: age, sex, liver etiologies, malignancy grades, Epstein-Barr virus status, performance status (PS), Ann Arbor stage, international prognostic index, and histopathological diagnosis. Of 1849 recipients, 79 PTLD lesions (4.3%) were identified in 70 patients (3.8%). After excluding 3 autopsy cases incidentally found, 67 (45 pediatric [5.1%] and 22 adult [2.3%]) patients were finally enrolled. Comorbid PTLDs significantly worsened recipient survival compared with non-complicated cases (P < 0.001). The 3-year, 5-year, and 10-year overall survival rates after PTLD diagnosis were 74%, 66%, and 58%, respectively. The incidence of PTLDs after LT (LT-PTLDs) was significantly higher (P < 0.001) with earlier onset (P = 0.002) in children, whereas patient survival was significantly worse in adults (P = 0.002). Univariate and multivariate analyses identified the following 3 prognostic factors: age at PTLD diagnosis ≥18 years (hazard ratio [HR], 11.2; 95% confidence interval [CI], 2.63-47.4; P = 0.001), PS ≥2 at diagnosis (HR, 6.77; 95% CI, 1.56-29.3; P = 0.01), and monomorphic type (HR, 6.78; 95% CI, 1.40-32.9; P = 0.02). A prognostic index, the "LT-PTLD score," that consists of these 3 factors effectively stratified patient survival and progression-free survival (P = 0.003 and <0.001, respectively). In conclusion, comorbid PTLDs significantly worsened patient survival after LT. Age ≥18 years and PS ≥2 at PTLD diagnosis, and monomorphic type are independent prognostic factors, and the LT-PTLD score that consists of these 3 factors may distinguish high-risk cases and guide adequate interventions.
Identifiants
pubmed: 33655645
doi: 10.1002/lt.26034
pmc: PMC8453854
pii: 01445473-202108000-00013
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165-1180Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20hm0102063h0003
Informations de copyright
Copyright © 2021 The Authors. Liver Transplantation published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106–112.
Dierickx D, Habermann TM. Post‐transplantation lymphoproliferative disorders in adults. N Engl J Med 2018;378:549–562.
Bhat M, Mara K, Dierkhising R, Watt KD. Gender, race and disease etiology predict de novo malignancy risk after liver transplantation: insights for future individualized cancer screening guidance. Transplantation 2019;103:91–100.
Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010;10:1889–1896.
Miyazaki T, Sato S, Kondo T, Kusaka M, Gotoh M, Saiki Y, et al. National survey of de novo malignancy after solid organ transplantation in Japan. Surg Today 2018;48:618–624.
Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, et al. Post‐transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol 2013;31:1302–1309.
Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222–230.
Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, et al. Single‐center analysis of biopsy‐confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 2013;54:2433–2440.
Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772–778.
Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post‐transplantation lymphoproliferative disorders. J Clin Oncol 2005;23:7574–7582.
Choquet S, Oertel S, LeBlond V, Riess H, Varoqueaux N, Dörken B, et al. Rituximab in the management of post‐transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007;86:599–607.
Hourigan MJ, Doecke J, Mollee PN, Gill DS, Norris D, Johnson DW, et al. A new prognosticator for post‐transplant lymphoproliferative disorders after renal transplantation. Br J Haematol 2008;141:904–907.
Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post‐transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038–1046.
Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. Br J Haematol 2015;171:491–500.
Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20‐year experience. Ann Surg 2002;236:429–437.
Tanaka K, Kiuchi T, Kaihara S. Living related liver donor transplantation: techniques and caution. Surg Clin North Am 2004;84:481–493.
Morioka D, Egawa H, Kasahara M, Ito T, Haga H, Takada Y, et al. Outcomes of adult‐to‐adult living donor liver transplantation: a single institution's experience with 335 consecutive cases. Ann Surg 2007;245:315–325.
Kubota T, Hata K, Sozu T, Ueda Y, Hirao H, Okamura Y, et al. Impact of donor age on recipient survival in adult‐to‐adult living‐donor liver transplantation. Ann Surg 2018;267:1126–1133.
Kusakabe J, Hata K, Tanaka S, Omae K, Okamura Y, Tajima T, et al. Prognostic index consisting of early post‐transplant variables <2 weeks in adult living‐donor liver transplantation. Hepatol Res 2020;50:741–753.
Uemura T, Wada S, Kaido T, Mori A, Ogura Y, Yagi S, et al. How far can we lower graft‐to‐recipient weight ratio for living donor liver transplantation under modulation of portal venous pressure? Surgery 2016;159:1623–1630.
Ogura Y, Hori T, El Moghazy WM, Yoshizawa A, Oike F, Mori A, et al. Portal pressure <15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl 2010;16:718–728.
Egawa H, Ohmori K, Haga H, Tsuji H, Yurugi K, Miyagawa‐Hayashino A, et al. B‐cell surface marker analysis for improvement of rituximab prophylaxis in ABO‐incompatible adult living donor liver transplantation. Liver Transpl 2007;13:579–588.
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658–663.
Demetris AJ, Bellamy C, Hübscher SG, O'Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody‐mediated rejection. Am J Transplant 2016;16:2816–2835.
Shehata MR, Yagi S, Okamura Y, Iida T, Hori T, Yoshizawa A, et al. Pediatric liver transplantation using reduced and hyper‐reduced left lateral segment grafts: a 10‐year single‐center experience. Am J Transplant 2012;12:3406–3413.
Gulley ML, Tang W. Laboratory assays for Epstein‐Barr virus‐related disease. J Mol Diagn 2008;10:279–292.
Gulley ML, Tang W. Using Epstein‐Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010;23:350–366.
Galera P, Flavin R, Savage NM, Saksena A, Gong S, Wang HY, et al. Epstein‐Barr virus‐negative marginal zone lymphoma as an uncommon form of monomorphic posttransplant lymphoproliferative disorder. Am J Surg Pathol 2020;44:1340–1352.
Hart M, Thakral B, Yohe S, Balfour HH Jr, Singh C, Spears M, et al. EBV‐positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am J Surg Pathol 2014;38:1522–1529.
Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, et al. Diagnosis of post‐transplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS guidelines. Br J Haematol 2010;149:675–692.
Tsao L, Chu KE, Bhagat G, Alobeid B. Development of hairy cell leukemia in a patient after cardiac transplantation. Leuk Lymphoma 2006;47:361–363.
Tsurusawa M, Mori T, Kikuchi A, Mitsui T, Sunami S, Kobayashi R, et al. Improved treatment results of children with B‐cell non‐Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B‐NHL03 study. Pediatr Blood Cancer 2014;61:1215–1221.
Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 2001;37:1–3.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860–1861.
International Non‐Hodgkin's Lymphoma Prognostic Factors Project . A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, et al. Decreasing incidence of symptomatic Epstein‐Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transpl 2013;19:730–740.
Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009;27:3354–3362.
Ho M, Miller G, Atchison RW, Breinig MK, Dummer JS, Andiman W, et al. Epstein‐Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985;152:876–886.
Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, et al. Immunohistology of Epstein‐Barr virus‐associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990;49:944–953.
Cockfield SM. Identifying the patient at risk for post‐transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:70–78.
Luzuriaga K, Sullivan JL. Infectious mononucleosis [published correction appears in N Engl J Med 2010 Oct 7;363(15):1486]. N Engl J Med 2010;362:1993–2000.
McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients [published correction appears in Transplantation 1999 Sep 27;68(6):909. Lee GS [corrected to Kim GS]]. Transplantation 1998;66:1604–1611.